Compare Moderna, Inc. (MRNA) vs Prologis Inc (PLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Prologis Inc — how do they compare? Moderna, Inc. trades at $136.91 (market cap $56.02B), while Prologis Inc trades at $135.35 (market cap $131.60B). The key difference: Prologis Inc is far larger — about 2.3× Moderna, Inc.'s market cap, and Prologis Inc pays a 3.09% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | PLD | |
|---|---|---|
Market Cap | $56.02B | $131.60B |
Sector | Health | Real Estate |
52-Week High | $174.38 | $149.96 |
52-Week Low | $22.36 | $110.98 |
Enterprise Value | $52.17B | $166.34B |
Dividend Yield | — | 3.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
Prologis (PLD) trades at $138.49, up 0.84% today, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue grew to $8.79B in 2025, and the company maintains high profit margins. Analyst consensus is bullish with a $160.13 price target, though technical indicators show near-term pressure with support at $137.
The outlook for PLD is positive due to consistent earnings beats and robust institutional interest, but risks include rising debt levels and market volatility. The stock offers growth potential from its real estate portfolio, yet investors should monitor debt-to-asset trends and economic conditions affecting REIT valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →
